#USA #Boston #AI Technology #Outcomes4Me #Cancer Care

Outcomes4Me Secures $21 Million in Funding to Transform Cancer Care

Outcomes4Me, based in Boston, is a trailblazer in cancer care by leveraging artificial intelligence (AI) to create a revolutionary direct-to-patient platform. Recently, the company announced that it has successfully closed a funding round of $21 million, which is set to expedite its efforts in enhancing patient treatment experiences and expanding its market reach.

Maya R. Said, Sc.D., the founder and CEO of Outcomes4Me, emphasized the significance of this investment, stating, "AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale." With upwards of 280,000 patients currently utilizing their AI-driven platform, Outcomes4Me is not just providing a service; it is empowering patients with real-time insights that guide them through every facet of their healthcare journey. The influx of funds will aid in enhancing their platform's capabilities and fostering substantial revenue growth.

AI at the Core of Cancer Care Innovation

At the heart of Outcomes4Me's mission is a commitment to deliver digital, data-centric, and personalized cancer care. Their AI-powered platform amalgamates various essential tools — from clinical guidelines and genomic insights to medication tracking and peer community support into one seamless interface. This approach allows patients to receive tailored treatment recommendations that are informed by real-time data. By merging innovative AI technologies with extensive oncology expertise, Outcomes4Me aims to boost the pace of advancements in cancer care, significantly enhancing patient outcomes and ensuring sustainable revenue growth.

Partnerships with Leading Investors

The recent funding round not only attracted new investors, including London-based Salica Investments, but also included existing backers such as Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD. This brings Outcomes4Me's total capital raised to an impressive $38 million to date, showcasing significant investor confidence in the company's innovative vision.

Demonstrated Success and Recognition

Since its commercial debut in 2022, Outcomes4Me has experienced remarkable revenue growth, reflecting a growing demand for more intelligent and personalized cancer care solutions. Currently, seven of the top 10 global pharmaceutical companies focused on oncology count Outcomes4Me among their valued partners, solidifying its status as a leader within the market.

The company has received recognition for its efforts, with over 15 industry awards in the past three years, including a nod from Fast Company as a World Changing Idea. The company also showcased significant growth, landing at #12 in the Inc. Regionals Northeast 2025 list, a significant leap from #70 in the previous year. Furthermore, Dr. Maya R. Said was recently honored as a finalist in the 2025 EY Entrepreneur of the Year program for New England.

An independent peer-reviewed study published in Current Oncology affirmed the platform's efficacy, marking it as the highest quality application among over 3,000 cancer-related resources globally.

A Vision for Global Expansion

Looking toward the future, Outcomes4Me is gearing up for expansive growth beyond American borders. The company's goal is to elevate global cancer care standards via strategic international ventures. The newly acquired funding will permit Actions such as:

• - Accelerating market penetration across a diversified array of cancer types and geographic regions.
• - Utilizing proprietary datasets to enhance its AI capabilities for more precise, real-time treatment suggestions.
• - Strengthening collaborations with top-tier health systems and life sciences firms on a global scale.
• - Exploring new revenue models through innovative partnerships and international expansion.
• - Generating outcomes-based evidence and real-world data insights to refine treatment protocols.

About Outcomes4Me

Outcomes4Me is distinguished as the first and only comprehensive AI-driven platform that empowers cancer patients. It enables individuals to engage actively in their care from diagnosis throughout every stage of treatment. The platform integrates critical aspects of clinical practice, such as treatment guidelines, genomic data, trial matching, and symptoms monitoring, to guide patients through their healthcare journey with confidence. Through its patented technology, Outcomes4Me is not merely redefining cancer care; it is pioneering smarter, more self-directed health solutions that grant patients control over their treatment choices. As a woman-led entity comprised of experts in healthcare, oncology, pharmaceuticals, technology, and consumer services, Outcomes4Me stands poised to redefine cancer care paradigms worldwide. For more information, visit www.outcomes4me.com.